Literature DB >> 17219032

Reasons to withhold intra-arterial thrombolysis in clinical practice.

J Isenegger1, K Nedeltchev, M Arnold, U Fischer, G Schroth, L Remonda, H P Mattle.   

Abstract

BACKGROUND: In selected stroke centers intra-arterial thrombolysis (IAT) is used for the treatment of acute stroke patients presenting within 6 hours of symptom onset. However, data about eligibility of acute stroke patients for IAT in clinical practice are very scarce.
METHODS: We collected prospectively data on indications advising for or against IAT of 230 consecutive stroke patients in a tertiary stroke center.
RESULTS: 76 patients (33.0%) presented within 3 hours, 69 (30%) between 3 and 6 hours of symptom onset and 85 (37%) later than 6 hours. Arteriography was performed in 71 patients (31%) and IAT in 46 (20%). In 11 patients no or only peripheral branch occlusions were seen on arteriography and therefore IAT was not performed. In 9 patients the ICA was occluded and barred IAT and in five anatomical or technical difficulties made IAT impossible. 72 patients presenting within 6 hours did not undergo arteriography and thrombolysis, mostly because of mild (n=44) or rapidly improving neurological deficits (n=13). Other reasons to withhold IAT were CT and/or clinical findings suggesting lacunar stroke due to small vessel occlusion (n=7), limiting comorbidty (n=7) and baseline international normalized ratio>1.7 (n=1).
CONCLUSIONS: A third of the patients underwent diagnostic arteriography and one fifth received IAT. The most important reasons to withhold thrombolysis were presentation beyond the 6 hours time window and mild or rapidly improving symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17219032     DOI: 10.1007/s00415-006-0220-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

2.  Blood pressure and vessel recanalization in the first hours after ischemic stroke.

Authors:  Heinrich P Mattle; Liliane Kappeler; Marcel Arnold; Urs Fischer; Krassen Nedeltchev; Luca Remonda; Stephan M Jakob; Gerhard Schroth
Journal:  Stroke       Date:  2005-01-06       Impact factor: 7.914

3.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

4.  Cuyahoga County Operation Stroke speed of emergency department evaluation and compliance with National Institutes of Neurological Disorders and Stroke time targets.

Authors:  Irene L Katzan; Thomas M Graber; Anthony J Furlan; Sophia Sundararajan; Cathy A Sila; Gary Houser; Dennis M Landis
Journal:  Stroke       Date:  2003-03-06       Impact factor: 7.914

5.  Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.

Authors:  J C Grotta; W S Burgin; A El-Mitwalli; M Long; M Campbell; L B Morgenstern; M Malkoff; A V Alexandrov
Journal:  Arch Neurol       Date:  2001-12

6.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.

Authors:  Werner Hacke; Greg Albers; Yasir Al-Rawi; Julien Bogousslavsky; Antonio Davalos; Michael Eliasziw; Michael Fischer; Anthony Furlan; Markku Kaste; Kennedy R Lees; Mariola Soehngen; Steven Warach
Journal:  Stroke       Date:  2004-11-29       Impact factor: 7.914

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis.

Authors:  M Arnold; K Nedeltchev; G Schroth; R W Baumgartner; L Remonda; T J Loher; F Stepper; M Sturzenegger; B Schuknecht; H P Mattle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

9.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

10.  Selective intra-arterial fibrinolysis of acute central retinal artery occlusion.

Authors:  J Weber; L Remonda; H P Mattle; U Koerner; R W Baumgartner; M Sturzenegger; C Ozdoba; F Koerner; G Schroth
Journal:  Stroke       Date:  1998-10       Impact factor: 7.914

View more
  2 in total

1.  Implementation of a patient selection protocol for intra-arterial therapy increases treatment rates in patients with acute ischemic stroke.

Authors:  Natalia S Rost; Eric E Smith; Raul G Nogueira; Kaitlin M Fitzpatrick; Albert J Yoo; Joshua A Hirsch; Lee H Schwamm
Journal:  J Neurointerv Surg       Date:  2012-05-18       Impact factor: 5.836

2.  Visible Thrombolysis Acceleration of a Nanomachine Powered by Light-Driving F0F1-ATPase Motor.

Authors:  Xiaoxia Duan; Lifeng Liu; Weijian Jiang; Jiachang Yue
Journal:  Nanoscale Res Lett       Date:  2015-05-21       Impact factor: 4.703

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.